吉非替尼一线治疗非小细胞肺癌脑膜转移１２例分析

目的　观察吉非替尼作为非小细胞肺癌（ＮＳＣＬＣ）脑膜转移一线治疗方案的疗效和不良反应。方法　１２例ＮＳＣＬＣ脑膜转移患者服用吉非替尼２５０ｍｇ，１／日，直至疾病进展。结果　１２例患者获ＣＲ８.３％，ＰＲ４１.７％，ＤＣＲ７５.０％，中位总生存期１０.２个月，中位无进展生存期７.８个月。药物引起的毒副反应大部分为１～２级，未因不良反应而减停。结论　吉非替尼一线用于ＮＳＣＬＣ脑膜转移安全有效，值得进一步研究。

Meningeal carcinomatosis treated by gefitinib as first-line therapy for non-small cell lung cancer: a 12 cases report

Objective To evaluate the efficacy and toxicity of gefitinib as the first-line therapy for non-small cell lung cancer（NSCLC） patients with meningeal carcinomatosis.Methods Totally,12 patients were enrolled and given gefitinib 250mg per day untill disease progressed.Results For all enrolled patients,CR was 8.3%,PR 41.7%,DCR 75.0%,median OS 10.2 months,and median PFS 7.8months.Most drug-related adverse events were mild and tolerable.No patients received reduced dosage or discontinued treatment because of side effects.Conclusion Gefitinib is effective and safe in patients with meningeal carcinomatosis from NSCLC and worth further study.